Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
AssigneeDelenex Therapeutics AG
InventorsAdrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
Life of this patent
Estimating the term…
Abstract
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
Claims16
A method for the treatment of glioblastoma in a subject suffering therefrom comprising administering to the subject a monoclonal antibody or antigen binding fragment thereof, wherein said antibody or fragment specifically binds human ALK protein, said antibody comprising a heavy chain variable region (VH) domain and a light chain variable region (VL) domain, said heavy chain variable region domain comprising the 3 CDRs in SEQ ID NO:
- 4 and said light chain variable region domain comprising the 3 CDRs in SEQ ID NO:5, thereby treating glioblastoma in the subject.
A method for the treatment of glioblastoma in a subject suffering therefrom, comprising administering to the subject an monoclonal antibody or antigen binding fragment thereof, wherein said antibody or fragment specifically binds human ALK protein, said antibody comprising a heavy chain variable region domain comprising the sequence of SEQ ID NO:4 and a light chain variable region domain comprising the sequence of SEQ ID NO:5, thereby treating glioblastoma in the subject.
Dependencies are inferred from the claim text.